Merck & Co., Inc. (FRA:6MK)
68.50
-0.70 (-1.01%)
Last updated: May 21, 2025
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B USD in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
2.94
Revenue / Employee
$852.29K
Employees
75,000
Market Cap
173.90B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 107.35B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Energy AG | 37.44B |
Siemens Healthineers AG | 23.14B |
Merck & Co. News
- 6 hours ago - Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Business Wire
- 7 hours ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 22 hours ago - Spotlight on Merck & Co: Analyzing the Surge in Options Activity - Benzinga
- 1 day ago - Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival - MarketWatch
- 2 days ago - I'm Putting Cash To Work: 2 Rock-Solid Dividends At Bargain Prices - Seeking Alpha
- 5 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Wallstreet:Online
- 5 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire
- 5 days ago - Decoding Merck & Co's Options Activity: What's the Big Picture? - Benzinga